Human CD19(M75V;R76S;F85S) Protein; hFc Tag

Size

£177.00

SKU:: PME101558
Additional Names:: B4; CVID3
Molecular Weight:: The protein has a predicted molecular mass of 56.1 kDa after removal of the signal peptide. The apparent molecular mass of CD19(M75V;R76S;F85S)-hFc is approximately 55-100 kDa due to glycosylation.
Purity:: The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.
Storage Conditions:: Store at -20[o]C to -80[o]C for 12 months in lyophilized form. After reconstitution; if not intended for use within a month; aliquot and store at -80[o]C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Supplier:: DIMA Biotechnology Ltd
Formulation:: Lyophilized from sterile PBS; pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Target:: CD19
CD19(M75V;R76S;F85S)(Pro20-Lys291) hFc(Glu99-Ala330):: CD19(M75V;R76S;F85S)(Pro20-Lys291) hFc(Glu99-Ala330)
Extra Details:: This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain; a hydrophobic transmembrane domain; and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia; an inability to mount an antibody response to antigen; and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq; Jul 2020]

Shipping Conditions:: Ambient